Insulet Corp. shares fell 6% after a securities class action lawsuit alleged the insulin pump maker misled investors about device safety issues, according to a July 15 filing. The case exposes Insulet to potential financial liability and regulatory scrutiny.
Insulet Corp. shares fell 6% after a securities class action lawsuit alleged the insulin pump maker misled investors about device safety issues, according to a July 15 filing.
"Insulet and certain senior executives violated federal securities laws by making materially false and misleading statements," Bleichmar Fonti & Auld LLP, the law firm representing investors, said in the complaint.
The lawsuit, filed in federal court, claims Insulet failed to disclose safety problems with its devices that later became public, triggering the share decline. A separate investigation was also announced by DJS Law Group on behalf of shareholders.
The case exposes Insulet to potential financial liability and heightened regulatory scrutiny at a time when medical device safety is under increased attention from the US Food and Drug Administration. The company has not yet responded to the allegations.
Insulet, based in Acton, Massachusetts, manufactures the Omnipod line of tubeless insulin pumps for diabetes management. The company trades on the Nasdaq under the ticker PODD.
The lawsuit seeks class-action status for investors who purchased Insulet securities during the period when the alleged misrepresentations occurred, according to the filing. Lead plaintiff deadlines remain open.
The case adds to competitive pressures for Insulet, which faces challenges from Medtronic Plc's MiniMed 780G system and Tandem Diabetes Care Inc.'s t:slim X2 pump in the insulin delivery market. The broader medical device sector has seen increased scrutiny over product safety disclosures, with similar securities lawsuits filed against other device makers in recent years.
This article is for informational purposes only and does not constitute investment advice.
